Compare USEG & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USEG | IPSC |
|---|---|---|
| Founded | 1966 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1M | 49.8M |
| IPO Year | N/A | 2021 |
| Metric | USEG | IPSC |
|---|---|---|
| Price | $0.99 | $0.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $3.50 | $3.00 |
| AVG Volume (30 Days) | 242.0K | ★ 927.3K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $9,484,000.00 | ★ $113,337,000.00 |
| Revenue This Year | N/A | $1,590.09 |
| Revenue Next Year | $57.52 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 4122.69 |
| 52 Week Low | $0.94 | $0.34 |
| 52 Week High | $6.40 | $1.38 |
| Indicator | USEG | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 41.82 | 52.80 |
| Support Level | $0.99 | $0.50 |
| Resistance Level | $1.05 | $0.62 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 14.22 | 55.62 |
US Energy Corp is an independent energy company. It is focused on the acquisition and development of oil and natural gas-producing properties in the continental United States. It has business properties and operations in the Rockies region (Montana, Wyoming, and North Dakota), the Mid-Continent (Oklahoma, Kansas, and North and East Texas), and the West Texas, South Texas, and Gulf Coast regions. The company generates revenue from its interest in the sales of oil and natural gas production. The group operates in the exploration and production segment of the oil and gas industry, onshore in the United States.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.